RT DogeDesigner (@cb_doge)🚨BREAKING: Neuralink’s first patient in the UK, Paul, who is paralyzed by motor neuron disease, has received a brain implant.Just hours after surgery, he was able to control a computer with his thoughts and is now using it to play games and regain independence. https://t.co/3u5nh4RCYu ...

India-based Miraqules developed a nanotechnology that mimics blood clotting proteins to quickly stop heavy bleeding. https://t.co/TxBkiMqXiF ...

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging powerhouse in botanical-based biotechnology, today announced the upcoming launch of its Investor Relations (IR) Presentation and Microsite — a major step in the company’s mission to deliver next-level transparency, elevate investor engagement, and align its communications with the highest standards of corporate governance. Building the Foundation for Lift-Off The IR Presentation initiative is driven by two key object ...

Core Viewpoint - Novartis defends its $12 billion acquisition of Avidity Biosciences, stating it is an appropriate risk ahead of upcoming late-stage data for Avidity's muscle disorder treatment [1][2] Group 1: Acquisition Details - The acquisition price is set at $72 per share, representing a 46% premium over Avidity's previous closing price [2] - This deal is the second-largest biotech acquisition of the year, following Johnson & Johnson's $14.6 billion purchase [3] - It marks the largest acquisition for Novartis under CEO Vas Narasimhan, who has been in the role since 2018 [4] Group 2: Strategic Rationale - The acquisition is part of Novartis' strategy to bolster its pipeline ahead of patent expirations for key drugs like Entresto and Xolair [4] - Avidity's late-stage therapies target rare neuromuscular disorders, with one therapy, Del-zota, expected to seek FDA approval next year [5] - Analysts view Avidity's therapies as a natural fit for Novartis' rare disease portfolio, although the acquisition price is considered higher than typical bolt-on deals [6][7] Group 3: Market Reaction - Following the announcement, Novartis' shares fell by 1.5%, while Avidity's stock surged over 40% [2] - The deal signals a potential increase in M&A activity within the biotech sector, driven by lower valuations and recent drug pricing agreements in the U.S. [3]

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.The Dow traded up 0.51% to 47,449.22 while the NASDAQ rose 1.68% to 23,593.80. The S&P 500 also rose, gaining, 1.01% to 6,860.11.Check This Out: Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For MondayLeading and Lagging SectorsCommunication services shares jumped by 1.5% on Monday.In trading on Monday, utilities stocks fell by 0.4%.Top HeadlineShares of Carter's Inc (N ...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.The Dow traded up 0.51% to 47,449.22 while the NASDAQ rose 1.68% to 23,593.80. The S&P 500 also rose, gaining, 1.01% to 6,860.11.Check This Out: Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For MondayLeading and Lagging SectorsCommunication services shares jumped by 1.5% on Monday.In trading on Monday, utilities stocks fell by 0.4%.Top HeadlineShares of Carter's Inc (N ...

Performance Overview - Baron Health Care Fund increased 5.39% in Q3 2025, outperforming the Russell 3000 Health Care Index's 5.05% but underperforming the Russell 3000 Index's 8.18% [2][3] - Since inception on April 30, 2018, the Fund has achieved an annualized return of 9.30%, compared to 8.68% for the Benchmark and 14.48% for the Index [2][4] Key Contributors - Strong stock selection in biotechnology, particularly from argenx SE and Insmed Incorporated, contributed significantly to the Fund's performance [5] - Argenx's Vyvgart sales exceeded expectations, while Insmed's Brinsupri received U.S. approval, representing a $5 billion-plus opportunity [5][16] - Investments in health care services, particularly RadNet, Inc. and Heartflow, Inc., also added value, with RadNet's shares rising due to strong quarterly results and guidance [6][7][17] Key Detractors - Poor stock selection in health care equipment, particularly from Masimo Corporation and Boston Scientific Corporation, negatively impacted performance [8][9] - Eli Lilly's stock fell due to disappointing Phase 3 trial results for orforglipron, alongside broader regulatory uncertainties affecting the pharmaceutical sector [12][21] - The Fund's underweight position in Johnson & Johnson, which saw a 22.3% increase, also detracted from relative performance [12] Portfolio Structure - The Fund held 46 stocks, with a significant overweight in biotechnology (31.8%) and health care equipment (24.0%), while being underweight in pharmaceuticals (15.2%) [24][28] - The top 10 holdings represented 47.8% of net assets, with Eli Lilly and argenx being the largest positions [26] Recent Activity - The Fund added 16 new positions and exited five, maintaining a focus on attractive valuations in the health care sector [29] - Notable purchases included AbbVie Inc., UnitedHealth Group, and Roivant Sciences, while positions in argenx and Eli Lilly were reduced to manage risk [30][31][37] Market Outlook - The health care sector is expected to offer attractive investment opportunities driven by demographic trends, chronic disease prevalence, and technological advancements [14][40] - Recent agreements, such as Pfizer's MFN pricing deal, are seen as positive for the pharmaceutical sector, with limited financial impact anticipated [38]

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders. If you currently own Amylyx stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about. ...

Breaking: Neuralink Implants Brain Chip in First UK PatientIn a milestone for neurotechnology, Neuralink has successfully implanted its brain-computer interface in its inaugural UK participant, Paul—a man paralyzed by motor neuron disease.The procedure took place at University College London Hospitals (UCLH) earlier this October. Remarkably, within hours of the surgery, Paul began using his thoughts to navigate and control a computer. Today, he’s collaborating with Neuralink’s team to leverage the device fo ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics ("MoonLake†or the "Company†) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the "Class Period†). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion. IF YOU SUFFER. ...